Please login to the form below

Not currently logged in
Email:
Password:

Michael Zaiac moves from GSK to Celgene

He takes up the role of VP, medical affairs, haematology-oncology EMEA

Celgene Michael ZaiacCelgene has appointed Michael Zaiac as vice president, medical affairs for its EMEA haematology-oncology business.

Zaiac joins the company's Switzerland-based international business from GlaxoSmithKline, where he was most recently franchise medical head for its immuno-inflammation and infectious diseases operations.

Prior to joining the pharmaceutical industry Zaiac served for several years as senior house officer in the UK in general, orthopaedic and cardiothoracic surgery, as well as working in Germany in general and vascular surgery and surgical oncology.

Marie-France Tschudin, corporate vice president of haematology-oncology at Celgene International, said “I am really pleased to have Michael on board to head up our haematology-oncology medical affairs team.

“This is a really exciting time for Celgene in EMEA, with three European approvals already in 2015, two of which are in haematology-oncology. His expertise in this area will give us the strong support we need at this fast-moving time.”

13th May 2015

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics